These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 10967203)
41. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Tang-Christensen M; Larsen PJ; Göke R; Fink-Jensen A; Jessop DS; Møller M; Sheikh SP Am J Physiol; 1996 Oct; 271(4 Pt 2):R848-56. PubMed ID: 8897973 [TBL] [Abstract][Full Text] [Related]
42. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556 [TBL] [Abstract][Full Text] [Related]
43. Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies. Dachicourt N; Serradas P; Bailbé D; Kergoat M; Doaré L; Portha B J Endocrinol; 1997 Nov; 155(2):369-76. PubMed ID: 9415071 [TBL] [Abstract][Full Text] [Related]
44. Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. Calvo JC; Gisolfi CV; Blazquez E; Mora F Brain Res Bull; 1995; 38(5):435-9. PubMed ID: 8665266 [TBL] [Abstract][Full Text] [Related]
45. Differential effects of naloxone on the release of neurohypophysial hormones in normotensive and spontaneously hypertensive rats. Rosella-Dampman LM; Emmert SE; Keil LC; Summy-Long JY Brain Res; 1985 Jan; 325(1-2):205-14. PubMed ID: 3978414 [TBL] [Abstract][Full Text] [Related]
46. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus. Owji AA; Khoshdel Z; Sanea F; Panjehshahin MR; Shojaee Fard M; Smith DM; Coppock HA; Ghatei MA; Bloom SR Brain Res; 2002 Mar; 929(1):70-5. PubMed ID: 11852032 [TBL] [Abstract][Full Text] [Related]
47. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247 [TBL] [Abstract][Full Text] [Related]
48. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Ruiz-Grande C; Alarcón C; Mérida E; Valverde I Peptides; 1992; 13(1):13-6. PubMed ID: 1320261 [TBL] [Abstract][Full Text] [Related]
49. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. McMahon LR; Wellman PJ Pharmacol Biochem Behav; 1997 Nov; 58(3):673-7. PubMed ID: 9329057 [TBL] [Abstract][Full Text] [Related]
50. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Suzuki S; Kawai K; Ohashi S; Mukai H; Murayama Y; Yamashita K Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178 [TBL] [Abstract][Full Text] [Related]
51. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Rinaman L Am J Physiol; 1999 Nov; 277(5):R1537-40. PubMed ID: 10564228 [TBL] [Abstract][Full Text] [Related]
52. Pharmacological assessment of the site of action of opioids on the release of vasopressin and oxytocin in the rat. Van de Heijning BJ; Koekkoek-Van den Herik I; Maigret C; Van Wimersma Greidanus TB Eur J Pharmacol; 1991 May; 197(2-3):175-80. PubMed ID: 1680708 [TBL] [Abstract][Full Text] [Related]
53. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Wettergren A; Maina P; Boesby S; Holst JJ Scand J Gastroenterol; 1997 Jun; 32(6):552-5. PubMed ID: 9200286 [TBL] [Abstract][Full Text] [Related]
54. Effects of cholecystokinin and glucagon-like peptide 1 on the secretion of pancreatic polypeptide in mice. Ahrén B; Gingerich RL; Havel PJ Regul Pept; 1995 Nov; 59(3):297-302. PubMed ID: 8577934 [TBL] [Abstract][Full Text] [Related]
55. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431 [TBL] [Abstract][Full Text] [Related]
56. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. Herrmann-Rinke C; Vöge A; Hess M; Göke B J Endocrinol; 1995 Oct; 147(1):25-31. PubMed ID: 7490533 [TBL] [Abstract][Full Text] [Related]
57. Glucagon-like peptide-1 is a physiological incretin in rat. Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643 [TBL] [Abstract][Full Text] [Related]
58. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Wettergren A; Wøjdemann M; Holst JJ Peptides; 1998; 19(5):877-82. PubMed ID: 9663453 [TBL] [Abstract][Full Text] [Related]
59. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Gutniak MK; Larsson H; Heiber SJ; Juneskans OT; Holst JJ; Ahrén B Diabetes Care; 1996 Aug; 19(8):843-8. PubMed ID: 8842602 [TBL] [Abstract][Full Text] [Related]
60. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Bucinskaite V; Tolessa T; Pedersen J; Rydqvist B; Zerihun L; Holst JJ; Hellström PM Neurogastroenterol Motil; 2009 Sep; 21(9):978-e78. PubMed ID: 19453518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]